readthroughSign in
Oct 22, 2026Weekly roundup

Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trials

Eli Lilly's DICE Therapeutics subsidiary reported results from two completed DC-806 interaction studies, while Lilly registered Phase 3 trials for EloraTZP in obesity and continued recruiting a pediatric orforglipron.

Lilly's week included results from two completed Phase 1 studies run through its DICE Therapeutics subsidiary, plus three newly registered or ongoing late-stage trials across its obesity and diabetes portfolio.

  • A completed Phase 1 study examined DC-806's pharmacokinetics when given alone, with itraconazole, and with carbamazepine in healthy adult volunteers1. The trial was sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company1, enrolled 33 participants1, and results were first posted October 19, 2026.
  • A second completed Phase 1 study looked at how DC-806 affected the pharmacokinetics of several CYP450 and transporter probe drugs, including midazolam, repaglinide, digoxin, and rosuvastatin, in healthy participants2. The study enrolled 28 participants2 and also had results posted October 19, 2026.
  • Lilly registered a Phase 3 trial, "AMPLIFY-1," testing its eloralintide and tirzepatide coformulation (EloraTZP) against tirzepatide, eloralintide alone, and placebo for weight reduction in adults with obesity but without type 2 diabetes. The study, assigning participants to EloraTZP at five dose levels, tirzepatide, eloralintide, or placebo, all given subcutaneously3, plans to enroll 2115 participants3 and is not yet recruiting, with an estimated start of December 2026.
  • A companion Phase 3 trial, "AMPLIFY-2," will compare EloraTZP against tirzepatide in adults with obesity or overweight who also have type 2 diabetes. The study plans to enroll 1000 participants4 with obesity, overweight, and type 2 diabetes4 and is not yet recruiting, with an estimated start of November 2026.
  • Lilly's pediatric Phase 3 trial "ACHIEVE-PEDS," comparing once-daily oral orforglipron against once-weekly dulaglutide in participants 10 to less than 18 years of age with type 2 diabetes5, continued recruiting. The study aims to enroll 170 participants5 and lists a primary completion estimate of March 2030.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.